Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Apr 17:4:81.
doi: 10.3389/fonc.2014.00081. eCollection 2014.

Modeling platinum sensitive and resistant high-grade serous ovarian cancer: development and applications of experimental systems

Affiliations
Review

Modeling platinum sensitive and resistant high-grade serous ovarian cancer: development and applications of experimental systems

Paula Cunnea et al. Front Oncol. .

Abstract

High-grade serous ovarian cancer remains the most common sub-type of ovarian cancer and, characterized by high degrees of genomic instability and heterogeneity, is typified by a transition from early response to acquired resistance to platinum-based chemotherapy. Conventional models for the study of ovarian cancer have been largely limited to a set of relatively poorly characterized immortalized cell lines and recent studies have called into question the validity of some of these as reliable models. Here, we review new approaches and models systems that take into account advances in our understanding of ovarian cancer biology and advances in the technology available for their generation and study. We discuss primary cell models, 2D, 3D, and organotypic models, and "paired" sample approaches that capture the evolution of chemotherapy failure within single cases. We also overview new methods for non-invasive collection of representative tumor material from blood samples. Adoption of such methods and models will improve the quality and clinical relevance of ovarian cancer research.

Keywords: high-grade serous ovarian cancer; platinum sensitive; resistant; tumor heterogeneity.

PubMed Disclaimer

References

    1. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature (2011) 474:609–1510.1038/nature10166 - DOI - PMC - PubMed
    1. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer (2003) 3:502–1610.1038/nrc1123 - DOI - PubMed
    1. Cooke SL, Ng CK, Melnyk N, Garcia MJ, Hardcastle T, Temple J, et al. Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma. Oncogene (2010) 29:4905–1310.1038/onc.2010.245 - DOI - PMC - PubMed
    1. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer (2007) 7:573–8410.1038/nrc2167 - DOI - PubMed
    1. Hirte HW, Clark DA, Mazurka J, O’Connell G, Rusthoven J. A rapid and simple method for the purification of tumor cells from ascitic fluid of ovarian carcinoma. Gynecol Oncol (1992) 44:223–610.1016/0090-8258(92)90046-L - DOI - PubMed